Myriad Genetics Inc. (MYGN)
-NasdaqGS 33.01 
0.05(0.15%) 4:00PM EDT|After Hours
:
33.23 0.22 (0.68%) 4:03PM EDT
| Prev Close: | 33.06 |
|---|
| Open: | 33.20 |
|---|
| Bid: | 33.02 x 100 |
|---|
| Ask: | 33.03 x 100 |
|---|
| 1y Target Est: | 32.83 |
|---|
| Beta: | 1.05 |
|---|
| Next Earnings Date: | 12-Aug-13 |
|---|
| Day's Range: | 33.00 - 33.49 |
|---|
| 52wk Range: | 22.02 - 34.70 |
|---|
| Volume: | 880,786 |
|---|
| Avg Vol (3m): | 1,171,770 |
|---|
| Market Cap: | 2.63B |
|---|
| P/E (ttm): | 21.05 |
|---|
| EPS (ttm): | 1.57 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Splicing & Dicing Myriad Genetics Amidst the Angelina Jolie Disclosureat Motley Fool(Tue 1:52PM EDT)
- QIAGEN Downgraded to Strong SellZacks(Tue 1:50PM EDT)
- Charting a persistent May uptrendat MarketWatch(Tue 12:07PM EDT)
- FDA Nod for COV's Advanced NellcorZacks(Tue 9:30AM EDT)
- U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancerat Bloomberg(Mon, May 20)
- The Implications of Monsanto's Supreme Court Winat Motley Fool(Sun, May 19)
- Myriad Genetics: Disruptive Products For Cancer Diagnosticsat Seeking Alpha(Sun, May 19)
- CE Mark for STJ's ILUMIEN OPTISZacks(Fri, May 17)
- Stryker Reiterated at NeutralZacks(Fri, May 17)
- SGEN's Adcetris under FDA ReviewZacks(Thu, May 16)
- Covidien Prices Senior NotesZacks(Thu, May 16)
- The Stock That May Have Saved Angelina Jolie's Life Could Get Another BoostStreetAuthority Network(Wed, May 15)
- Angelina Jolie's Selfless Act Heightens Breast Cancer Awarenessat Motley Fool(Wed, May 15)
- Genomic Health's New Prostate Test May Extend The Stock's Upward Climbat Seeking Alpha(Wed, May 15)
- Company That Sells Angelina Jolie’s Blood TestYCharts(Wed, May 15)
Key Statistics
| Forward P/E (1 yr): | 17.84 |
|---|
| P/S (ttm): | 4.60 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | 1.67 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.44 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | 1.43 |
|---|
Business Summary
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States.
View More